Skip to main content
SpringerLink
Log in

Platelet Cyclic GMP Responses to Nitroglycerin

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

The present study further investigates the use of platelet cyclic guanosine monophosphate (GMP) as a biochemical measure of tolerance. Platelet cyclic GMP has been reported as a marker of the biochemical effects of nitroglycerin (GTN) and as an indicator of the development of tolerance. Platelet cyclic GMP levels and systolic blood pressure (SBP) were measured repeatedly in nine subjects who received continuous transdermal GTN therapy (0.6 mg/hour), and in nine control subjects who did not. These measurements were also made before and after sublingual GTN (0.6 mg) in both groups. Whole blood from five subjects was incubated with normal saline (as a control), with 22 nM GTN (representing a therapeutic GTN concentration), and with 100 μM GTN. Although the acute administration of transdermal GTN caused a significant decrease in SBP (112 ± 3 to 96 ± 3 mmHg, p = 0.003), SBP returned to baseline following 1 week of continuous therapy. Platelet cyclic GMP levels did not change in response to transdermal GTN, either acutely or following sustained therapy. Similarly, sublingual GTN caused no change in platelet cyclic GMP in either group. There was no change in platelet cyclic GMP concentration following incubation with 22 nM GTN. Platelet cyclic GMP did increase following incubation with 100 μM GTN (0.883 +/−0.043 pmol/109 platelets, p < 0.001). These results demonstrate that platelet cyclic GMP levels do not change in response to clinically relevant doses of GTN. Literature supporting the use of platelet cyclic GMP levels as an index of GTN effects and/or tolerance should be interpreted with caution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Axelsson KL, Wikberg JES, Andersson RGG. Relationship between nitroglycerin, cyclic GMP and relaxation of vascular smooth muscle. Life Sci 1979;24:1779-1786.

    Google Scholar 

  2. Katsuki S, Murad F. Regulation of adenosine cyclic 30,50-monophosphate and guanosine cyclic 30,50-monophosphate and contractility in bovine tracheal smooth muscle. Mol Pharmacol 1977;13:330-341.

    Google Scholar 

  3. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, Gruetter CA. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitroprusside and nitrous oxide: evidence for the involvement of Snitrosothiols as active intermediates. J Pharmacol Exp Ther 1981;218:739-749.

    Google Scholar 

  4. Stewart DD. Remarkable tolerance of nitroglycerin. Philadelphia: Polyclinic 1888;VI:171-172.

    Google Scholar 

  5. Abrams J. Tolerance to organic nitrates. Circulation 1986;74:1181-1185.

    Google Scholar 

  6. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs Ther 1994;8:489-499.

    Google Scholar 

  7. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-194.

    Google Scholar 

  8. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-3531.

    Google Scholar 

  9. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983;88:71-79.

    Google Scholar 

  10. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 30,50-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-955.

    Google Scholar 

  11. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990;37:671-681.

    Google Scholar 

  12. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, Sugishita Y. Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993;88:29-36.

    Google Scholar 

  13. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997;96:2545-2550.

    Google Scholar 

  14. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Effects of enalapril during continuous nitrate therapy: analysis of diameter of coronary arteries and platelet cyclic guanosine monophosphate. Am Heart J 1997;134:614-621.

    Google Scholar 

  15. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. Jpn Circ J 1998;62:353-358.

    Google Scholar 

  16. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. Circulation 1998;97:886-891.

    Google Scholar 

  17. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J Am Coll Cardiol 1998;31:1323-1329.

    Google Scholar 

  18. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. J Cardiol 1998;31:173-181.

    Google Scholar 

  19. Aoki H, Inoue T, Mizobe T, Harada M, Imai H, Kobayashi A. Platelet function is inhibited by nitric-oxide liberation during nitroglycerin-induced hypotension anaesthesia. Br J Anaesth 1997;79:476-481.

    Google Scholar 

  20. Chirkov YY, Naujalis JI, Sage RE, Horowitz JD. Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol 1993;21:384-389.

    Google Scholar 

  21. Bassenge E, Fink N, Skatchkov M, Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 1998;102:67-71.

    Google Scholar 

  22. Armstrong PW, Armstrong JA, Marks GS. Blood levels after sublingual nitroglycerin. Circulation 1979;59:585-588.

    Google Scholar 

  23. Armstrong PW, Armstrong JA, Marks GS. Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. Circulation 1980;62:160-166.

    Google Scholar 

  24. Zimrin D, Reichek N, Bogin K, Aurigemma G, Douglas P, Berko B, H-LF. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376-1384.

    Google Scholar 

  25. Booth BP, Jacob S, Bauer JA, Fung HL. Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats. J Cardiovasc Pharmacol 1996;28:432-438.

    Google Scholar 

  26. Amado JA, Salas E, Botana MA, Poveda JJ, Berrazueta JR. Low levels of intraplatelet cGMP in IDDM. Diabetes Care 1993;16:809-811.

    Google Scholar 

  27. Radziszewski W, Chopra M, Zembowicz A, Gryglewski R, Ignarro LJ, Chaudhuri G. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins. Int J Cardiol 1995;51:211-220.

    Google Scholar 

  28. Anwaar I, Gottsater A, Wallmark A, Hedblad B, Lindgarde F, Mattiasson I. Intraplatelet cyclic 30-50 guanosine monophosphate is related to serum cholesterol. Int Angiol 1996;15:201-206.

    Google Scholar 

  29. Axelsson KL, Anderson RGG, Wikberg JES. Vascular smooth muscle relaxation by nitro compounds: reduced relaxation and cGMP elevation in tolerant vessels and reversal of tolerance by dithiothreitrol. Acta Pharmacol Toxicol (Copenh) 1982;50:350-357.

    Google Scholar 

  30. Rapoport RM, Waldman SA, Ginsburg R, Molina CR, Murad F. Effects of glyceryl trinitrate on endothelium-dependent and-independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol 1987;10:82-89.

    Google Scholar 

  31. Molina CR, Andresen JW, Rapoport RM, Waldman S, Murad F. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. J Cardiovasc Pharmacol 1987;10:371-378.

    Google Scholar 

  32. Bennett BM, Schroder H, Hayward LD, Waldman SA, Murad F. Effect of in vitro organic nitrate tolerance on relaxation, cyclic GMP accumulation, and guanylate cyclase activation by glyceryl trinitrate and the enantiomers of isoidide dinitrate. Circ Res 1988;63:693-701.

    Google Scholar 

  33. Tsutamoto T, Kinoshita M, Ohbayashi Y, Wada A, Maeda Y, Adachi T. Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure. Circulation 1994;90:823-829.

    Google Scholar 

  34. Tsutamoto T, Kinoshita M, Hisanaga T, Maeda Y, Maeda K, Wada A, Fukai D, Yoshida S. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 1995;75:1162-1165.

    Google Scholar 

  35. Fung HL. Solving the mystery of nitrate tolerance. A new scent on the trail? Circulation 1993;88:322-324.

    Google Scholar 

  36. Hebert D, Xiang JX, Lam JY. Persistent inhibition of platelets during continuous nitroglycerin therapy despite hemodynamic tolerance. Circulation 1997;95:1308-1313.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

    Douglas D. Martin

  2. Department of Clinical Biochemistry, The Toronto Hospital, University of Toronto, Toronto, Ontario, Canada

    Jeffrey S. Tong

  3. Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

    John D. Parker

Authors
  1. Douglas D. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey S. Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John D. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, D.D., Tong, J.S. & Parker, J.D. Platelet Cyclic GMP Responses to Nitroglycerin. Cardiovasc Drugs Ther 14, 419–425 (2000). https://doi.org/10.1023/A:1007868317306

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007868317306

Search

Navigation